The human epidermal growth factor receptor 2 (HER2) is specifically overexpressed in tumors of several cancers, including an aggressive form of breast cancer. It is therefore a target for both cancer diagnostics and therapy. The 58 amino acid residue ZHER2 affibody molecule was previously engineered as a high-affinity binder of HER2. Here we determined the structure of ZHER2 in solution and the crystal structure of ZHER2 in complex with the HER2 extracellular domain. ZHER2 binds to a conformational epitope on HER2 that is distant from those recognized by the therapeutic antibodies trastuzumab and pertuzumab. Its small size and lack of interference may provide ZHER2 with advantages for diagnostic use or even for delivery of therapeutic agents to HER2-expressing tumors when trastuzumab or pertuzumab are already employed. Biophysical characterization shows that ZHER2 is thermodynamically stable in the folded state yet undergoing conformational interconversion on a submillisecond time scale. The data suggest that it is the HER2-binding conformation that is formed transiently prior to binding. Still, binding is very strong with a dissociation constant K D ¼ 22 pM, and perfect conformational homogeneity is therefore not necessarily required in engineered binding proteins. A comparison of the original Z domain scaffold to free and bound ZHER2 structures reveals how high-affinity binding has evolved during selection and affinity maturation and suggests how a compromise between binding surface optimization and stability and dynamics of the unbound state has been reached.
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protein engineering | molecular recognition | protein-protein interactions | protein conformational dynamics | cancer therapy T he human epidermal growth factor receptor 2 (HER2, ErbB2) is a 185-kDa transmembrane glycoprotein receptor tyrosine kinase involved in the signal transduction pathways leading to cell growth and differentiation (1) . In contrast to the other three members of the epidermal growth factor receptor family, HER2 is thought to be an orphan receptor, i.e. lacking a ligand (2) . However, HER2 forms heterodimers with any of the related receptors, resulting in receptor activation. Enhanced levels of HER2 have been shown to correlate with one form of aggressive breast cancer, precipitating the development of the HER2-binding monoclonal antibodies (mAb) trastuzumab (3) and pertuzumab (4) . Trastuzumab is now established for treating breast cancers shown to be HER2 overexpressing. Pertuzumab binds to a separate site on HER2 (4) . It is more efficient at blocking HER2 heterodimerization (4, 5) , and it is in clinical trials for its effects on breast cancer and other cancers (6) . Trastuzumab conjugated to the microtubule-depolymerizing agent maytansinoid (trastuzumab-DM1) was recently shown to be even more efficacious than native trastuzumab, leading to high response rates in patients who failed trastuzumab therapy (7) . These findings agree with previous data indicating that cancer cells do not loose HER2 expression when they become refractory to trastuzumab, but that the biological context needed for efficacy of trastuzumab has been lost (8, 9) . Thus, the role of the antibody moiety in trastuzumab-DM1 is primarily to work as a carrier of a cytotoxin. This finding raises interest in evaluating other HER2-binding molecules displaying alternative properties compared to antibodies, including biodistribution. One such molecule is the affibody molecule Z HER2:342 (hereafter ZHER2), which binds HER2 with very high affinity
Affibody molecules were designed as an alternative to immunoglobulin-based binding proteins. The parental "Z domain" is a small protein of 58 amino acids organized into a three-helix bundle. It was developed as a stabilized variant of the "B domain" of the IgG-binding staphylococcal protein A (11) . The original affibody sequence diversity libraries were made by randomizing 13 surface-exposed amino acid residues on the IgG-binding surface of helices 1 and 2 (12) . Affibody molecules binding a variety of different target proteins have subsequently been selected from such libraries (13) .
The high affinity of ZHER2 for its HER2 target is a result of so-called affinity maturation, which is a second round of combinatorial protein engineering and phage display selection (10, 13) . ZHER2 competes with neither trastuzumab (14) nor pertuzumab (15) for HER2 binding. ZHER2 also does not appear to mediate detectable biological effects (16) . These properties make it suitable as a tracer when the aim is to study HER2 without affecting its function, even in the presence of therapeutic monoclonal antibodies. Hence, ZHER2 allows for molecular imaging of HER2 (15, 17) without interfering with ongoing therapy using either of the two mAbs. Alternatively, it may be used in synergy with any of these, if used as a carrier to direct additional therapeutic agents to their HER2 target.
The potential of the ZHER2 affibody molecule for diagnostic and therapeutic use motivates detailed characterization of its structural and biophysical properties. Previous structural studies of affibody molecules (18) (19) (20) have revealed a large variability in structure and binding interface, and it is therefore also interesting to learn how the binding surface evolves during affinity maturation. We find that ZHER2 adopts the standard three-helix bundle topology, but that the extensive mutagenesis in this case results in two or more similar conformations that interconvert on the submillisecond time scale. This dynamics is apparently not prohibitive of picomolar binding. We argue that it appears as a trade-off in affinity maturation when, for instance, intramolecular hydrogen bonds are sacrificed in order to optimize the HER2 binding surface. The crystal structure of the complex between ZHER2 and HER2 allows comparison of the structures of free and bound ZHER2 and shows that the binding site on HER2 is distant from the epitopes previously determined for trastuzumab and pertuzumab.
Results
Secondary Structure Content and Stability of Free ZHER2. The circular dichroism (CD) spectrum of ZHER2 (Fig. 1A) shows that α-helical secondary structure is dominating. The contribution from the disordered histidine tag to the CD at 222 nm is expected to be minimal (21) . If the CD signal at 222 nm originates only from the 58-residue affibody domain, then the mean residue ellipticity MRE 222 ¼ −26;100 deg cm 2 dmol −1 , which corresponds to a helix content of 73% or ca. 42 residues (22) . This value compares to 77% (ca. 45 residues) in the parental Z domain (23) . The thermal stability of the present affibody molecule is also good with a melting temperature of 67°C (Fig. 1B) , which is close to the 75°C of the Z domain at pH 7.2. We measured folding stability at room temperature by monitoring intrinsic protein fluorescence as function of guanidinium chloride denaturant concentration (Fig. 1C) there is more then one folded conformation, which we will show is the case here. However, one must consider the folded state(s) as a single thermodynamic state as long as interconverting conformations cannot be distinguished by the experiments, and as long as the two-state model fits the data as in Fig. 1 B and C.
The NMR Spectrum and Dynamics of Free ZHER2. The assigned 15 N NMR heteronuclear sequential quantum correlation (HSQC) spectrum of ZHER2 at 30°C is characterized by a large variation in NMR line shapes. These reveal at least four categories of dynamics on different time scales, as indicated by the coloring of resonances in Fig. 1D . Disordered residues at the N terminus are dynamic at the picosecond time scale with sharp NMR resonances. The residues in helix 3, most of helix 2, and in loop regions appear to be well ordered within the folded protein as judged from linewidths and a large number of NOE connectivities (Fig. S1 ). Resonances from helix 1, and from mutated regions of helix 2, are broadened due to conformational exchange on the microsecond to millisecond time scales. Some of these are too weak to be assigned, and most are in fact broadened beyond detection. Several Asn and Gln side chain resonances are also broadened, and there are at least three sets of unassigned resonances from Gln or Asn amino ( 15 NH 2 − ) groups in alternative slowly exchanging conformations. The same pattern of dynamics is apparent in the 13 C HSQC spectrum, where several resonances are undetectable and resonances from methyl groups at the hydrophobic interface of helices 1 and 2 are observable, but broadened.
We used NMR relaxation dispersion experiments (26) to determine the rate of conformational exchange. As expected from the line broadening, many amide 15 N resonances show a strong dependence of the R 2 relaxation rate on an external CPMG (Carr-Purcell-Meiboom-Gill) field (Fig. 1E) . Measured relaxation dispersion profiles could be fit to a two-state model of fast exchange (27) using a single global value of the exchange rate k ex ¼ 3574 AE 206 s −1 , which is the sum of forward and reverse interconversion rates. Best-fit R 2 relaxation rates and dispersion amplitudes confirm that helix 1 and helix 2 are involved in this interconversion, whereas loop regions and helix 3 are less affected (Fig. 1F) . The populations of interconverting states cannot be resolved in the fast exchange limit unless there is additional information on chemical shift differences. A global fit of 800-and 600-MHz relaxation data to the full Carver-Richards equation was still attempted to determine both populations and shift differences, but it did not converge.
Resonances from C-terminal residues 59 and 60 appear as doublets in the NMR spectrum (Fig. 1D ), indicating that they can adopt two slowly exchanging conformations. These are not part of the parental Z domain and on the DNA level they correspond to a restriction site introduced to enable facile multimerization. Conformational heterogeneity at the C terminus is unlikely to be of relevance for ZHER2 stability or binding.
Solution Structure of Free ZHER2. As many as 13 amide resonances in helices 1 and 2 could not be detected and assigned (Fig. 1D) , but other resonances in most of the corresponding side chains could still be sequentially assigned based on medium range d αβ ði;i þ 3Þ NOEs in the 3D 13 C-NOESY spectrum, and yet others were assigned based on residue type (for instance, Ala12). An ensemble of structures was calculated using simulated annealing (SA) based on distance restraints derived from NOE connectivities, backbone dihedrals derived from NMR chemical shifts, and backbone and side chain hydrogen bonds, which were added at the final stage of refinement (SI Text and Table S1 ). The structure of most of the molecule, including helix 3, most of helix 2, loop regions, and the hydrophobic core, is well defined (Fig. 2 A and B) .
However, the backbone conformation of helix 1 and around mutated regions of helix 2 could not be calculated at high precision. Hence, helix 1 appears as two helical fragments connected by a loop at residues 13 and 14 in minimized SA structures, and there are two conformations of residues 1 to 12 ( Fig. 2 B and C) . Still, chemical shifts and medium range NOE connectivities of all observable resonances in helix 1 suggest that it indeed could be completely helical. To examine this possibility, we calculated a set of alternative ZHER2 structures (ZHER2_ALT) in which an α-helical conformation of residues 6 to 14 was enforced, without removing or changing any experimental restraints. These SA calculations also converged to high-quality structures without violating any of the ca. 100 experimental restraints involving helix 1 (Table S1 ).
The reason why unbiased SA results in a distorted rather than an intact helix 1 is that the former is slightly favored by the structure calculation force field (conformational plus restraint energies of −499 AE 20 versus −472 AE 24 kcal mol −1 , respectively). However, an evaluation of Ramachandran statistics (Table S1) and packing of the hydrophobic core (Fig. 2D) suggest that an intact helix 1 is more favored. We conclude that both conformations are possible. It is not unlikely that the observed dynamics involves interconversion between these two conformations, as discussed below.
X-Ray Crystal Structure of HER2/ZHER2. The complex between the HER2 extracellular domain (HER2ecd) and ZHER2 was determined at 2.9-Å resolution ( Fig. 3 and Table S2 ). It shows ZHER2 bound to an epitope that includes residues from both domain III and domain IV of HER2. This region is not part of the epitopes in the previously characterized complexes of HER2ecd with Fab fragments of therapeutic antibodies trastuzumab or pertuzumab (Fig. 3A) , although it is part of a crystal packing interaction in the pertuzumab-Fab/HER2 complex (4). The conformational arrangement of HER2ecd domains is essentially the same as in previous studies (2, 4, 28) . Upon ZHER2 binding about 1;250 Å 2 of solvent accessible surface (1.4-Å probe radius), of which 58% is nonpolar, is sequestered on each side of the HER2ecd/ZHER2 interface, and the shape complementarity statistic is Sc ¼ 0.65. There are 25 residues from HER2ecd and 14 residues from ZHER2 that are within 4 Å of the binding partner. These form 11 direct interprotein hydrogen bonds with distances up to 3.3 Å (Fig. 3B and Table S3 ). These metrics are all consistent with the high-affinity binding.
The conformation of ZHER2 in the crystal structure includes a continuous helix 1 as in the alternate ZHER2_ALT NMR structure, which provides close contacts to HER2 along its entire length. The rms backbone differences between bound-state ZHER2 and the ZHER2 and ZHER2_ALT free-state structures are 1.4 and 1.0 Å, respectively, for alpha carbons of residues 6 to 56, and ∼3.0 and 0.9 Å for residues 6 to 13 (in helix 1). There is also mostly good correspondence with side chain conformations in bound-state ZHER2 and ZHER2_ALT, whereas side chain correspondence to the (nonalternate) solution structure is relatively poor for residues in helix 1. The mean temperature factor (B) for ZHER2 is the same as that for the entire complex structure, but B values are relatively high at the beginning of helix 1. ZHER2 residues preceding helix 1 were not resolved in electron density maps and are absent from the final coordinates.
Discussion
Conformational Dynamics in Free ZHER2. The present HER2-binding affibody molecule is thermodynamically stable and a very strong binder, but it undergoes conformational interconversions on the submillisecond time scale in the free state. There is a clear correlation between sites of mutation and dynamics (Fig. 2 A  and C-E) . ZHER2 has a melting temperature of 67°C, but it is somewhat less stable to unfolding than the parental Z domain or the B domain of staphylococcal protein A. Still, the conformational dynamics is not likely to be global unfolding, because one would then not expect the localized effects of line broadening observed here. Studies of the B domain show that global protein unfolding begins with helix 1 (29) . It is therefore possible that the observed dynamics is due to local unfolding of helix 1.
However, the average helicity observed by CD implies that a major fraction (>99%) of ZHER2 exists as a three-helix bundle at 20°C. An alternative explanation of the dynamics, which we favor, is therefore that it reflects interconversions between two or more folded conformations of helix 1. It is possible that two of these are the ones shown in Fig. 2 C and D, both of which are consistent with experimental data. Interconversion between only two conformations is supported by the 15 N R 2 relaxation dispersion data, but the presence of additional conformational states can on the other hand not be ruled out.
The fact that line broadening makes interconverting structures nearly indistinguishable in structure calculations can be explained: NMR resonances that would distinguish between conformations would be expected to experience the largest changes in chemical shift upon interconversion. These are therefore most Fig. 2A . Three varied side chains (Asn11, Gln25, and Lys27; not displayed) do not interact with HER2. Some of the observed intermolecular hydrogen bonds (Table S3 ) are shown as dashed lines.
affected by exchange line broadening, and the critical experimental discriminants (chemical shifts and NOEs) remain undetected as they disappear with line broadening. Previous structural studies of affibody molecules in complex with target proteins reveal that the three-helix scaffold of the Z domain may remain intact in the complex (19, 20) , but that the extensive mutagenesis also can lead to the selection of other very different conformations (18) . Affibody molecules may also differ in their folding stability and even be largely disordered while still showing strong binding (30) . The present HER2-binding affibody molecule represents yet another variation on these themes: It is thermodynamically stable and a very strong binder, but there is dynamics in mutated regions.
Conformational dynamics in engineered binding proteins will affect binding affinity, though the effect does not have to be large. For instance, if there are two equally populated interconverting states of ZHER2 of which one binds the HER2 receptor, the binding affinity is reduced by only 50%, in this case from a theoretical K D ¼ 11 pM to the observed K D ¼ 22 pM. Still, the dynamics leaves room for further optimization of binding affinity, perhaps by optimizing conformational stability as with the Z SPA-1 affibody molecule (31) .
A possible reason for destabilization and dynamics in ZHER2 is the replacement of Gln9 at the N-terminal end with Met9 and Glu24/Glu25/Asn28 at the C-terminal end with Asn24/Gln25/ Arg28. This is because as many as eight hydrogen bonds in the Z domain are lost by these mutations, and only a few alternative hydrogen bonds form (Fig. 4) . These replacements can therefore account for destabilization as well as dynamics of helix 1 and 2 and alternative conformations of Asn and Gln side chains at the C-terminal end (Figs. 1D and 2 C and D) . Homologous substitutions at positions 9, 24, and 25 could not be identified in initial selections from the full library (32) . These were therefore again randomized in the affinity maturation library resulting in selection of Met9 and Asn24 that together with the native Asn6 and the previously selected Arg28 participate in interactions with HER2 (Figs. 3B and 4) . Thus, although reinstating original residues might stabilize ZHER2, it will probably also affect binding affinity. We therefore suggest that affinity maturation has involved a trade-off between binding surface optimization and folding stability and/or structural homogeneity of unbound molecules in the library. Or in other words, stability has been sacrificed during the selections in order that new side chains can interact with HER2, and with free-state conformational lability and dynamics as by-products.
Bound-State ZHER2 Conformation and Interactions. The complex structure determined using X-ray crystallography is of sufficiently high resolution to permit confident placement of side chains. There is a good correspondence between the residues varied during initial selections and affinity maturation and those found in intimate association with HER2ecd. Of the 13 randomized amino acid positions, 10 are within 4 Å and 6 interact with HER2 via 11 hydrogen bonds (Fig. 3B and Fig. S2) . Overall, the bound-state coordinates of ZHER2 are clearly more similar to those of the alternate ZHER2_ALT than to the ZHER2 free-state structures, and most differences occur in regions that are dynamic in the free state. This is consistent with a transient population of the boundstate conformation in free ZHER2. Furthermore, relatively high temperature factors (B values) are observed for the first part of helix 1, where the two NMR structures differ the most. Hence, some of the flexibility observed with monomeric ZHER2 in solution probably remains in complex with HER2. The similarity between bound ZHER2 and ZHER2_ALT extends to almost all side chains at the binding surface. Exceptions are Trp14, for which the conformation is the same as in only 4 of 23 structures of the ZHER2_ALT ensemble, and Tyr35, which attains a ZHER2_ALT side chain conformation different from that in the bound state (χ 1 ¼ 180°versus 90°). Interactions with HER2 are clearly responsible for the conformations of these side chains in the complex, indicating that some conformational adaptation occurs also at the binding surface.
The high-affinity ZHER2 binding is accounted for by the structure. For instance, the binding surface is 50% larger than in any of the four other affibody molecules that have been structurally characterized (18) (19) (20) . This is because 10 of 13 varied side chains are involved, but also because interactions extend toward the N-terminal end of the molecule ( Fig. 3B; e.g., Asn6 and Pro38). The Ile31 side chain, which is native to the Z domain, is centrally located at the ZHER2 binding surface as in all other bound-state affibody or Z domain structures. It was suggested that Ile31 mediates some intrinsic property of Z domain binding that is inherited in affibody molecules (19) .
The HER2/ZHER2 interface also reveals how the evolution of ZHER2 into a high-affinity binder has occurred. First, residues Arg10 (or a Lys10), Trp13, Tyr14, Arg28, Arg32, and Tyr35 were all present in two initial binders obtained from a full library with 13 randomized positions (32) . These, together with Ile31, Asp36, and Pro38 that were not varied, already constitute the core binding surface (Fig. 3B ) that supports dissociation constants of K D ≈50 nM and K D ≈140 nM, respectively. The maturation library then allowed for optimization around the core HER2 interface. It contained six completely randomized positions and two positions with a more restricted variation. The side chains of Met9, Ala17, Leu18, and Asn24 at four of the six completely randomized positions were selected because they extend the interface and Arg10 was this time present in all selected binders. Presumably also the nonvaried Asn6 became involved at this point. Side chains at three remaining randomized positions that did not participate in binding then "returned" to those present in the original Z domain (Asn11) or as homologous side chains (Gln25 at the position of Glu25, and Lys27 replacing Arg27) to complete the high-affinity binder (10).
ZHER2 Recognizes a Previously Unexploited Epitope on the HER2 Receptor. The ZHER2 binding site on HER2 is distant from those of both trastuzumab and pertuzumab. This is consistent with the lack of interference between either trastuzumab or pertuzumab and ZHER2. Any antibodies that may have been raised against this epitope would probably not be well studied due to an absence of any effect on HER2 function. Nonetheless, the present structure demonstrates that this and other nominally occult epitopes are available for exploitation for imaging or for targeted delivery of linked chemotherapeutic agents. The relatively small size of ZHER2 and the associated reduced potential for steric overlap with therapeutic antibodies make it attractive for use as a molecular imaging tracer during antibody treatment. Indeed, a molecular imaging agent based on ZHER2 has been investigated clinically and has been shown to yield images of HER2 overexpressing metastases within hours after injection in patients also undergoing trastuzumab therapy (17) .
Materials and Methods
ZHER2 with an N-terminal His 6 tag (10) used for biophysical and NMR studies was produced in Escherichia coli and purified by immobilized metal ion chromatography followed by size exclusion chromatography (SEC). NMR was performed at 30°C on a ca. 1 mM uniformly 13 C; 15 N-labeled ZHER2 sample in 160 mM NaCl and 16 mM potassium phosphate at pH 6.0 with 0.1% NaN 3 and 5% D 2 O. Structures were calculated using simulated annealing with distance restraints derived from NOEs, backbone dihedral angle restraints derived from chemical shifts, and hydrogen bond restraints derived from hydrogen bonds observed in initially calculated structures. The 58 amino acid ZHER2 peptide used for X-ray crystallography was prepared by solid phase synthesis. HER2ecd was expressed in Chinese hamster ovary cells and purified by affinity chromatography using HERCEPTIN®, diethylaminoethane anion exchange, and SEC. Crystals of the HER2ecd:ZHER2 complex formed in sitting drops at 10 mg∕mL in 0.1 M NaCl, 5 mM MOPS (pH 7.3) and reservoir containing 15% wt∕vol PEG 3350, 0.1 M sodium acetate (pH 5.0), 0.2 M ammonium acetate. Diffraction data extending to 2.9-Å resolution was collected at ESRF beamline ID23-2. The structure was solved by molecular replacement.
Complete descriptions of protein production, biophysical characterization, NMR spectroscopy, and crystallography are in SI Text.
